Overview

Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.

Status:
Completed

Trial end date:
2008-08-01

Target enrollment:

Participant gender:

Summary

To evaluate the single dose relative bioavailability of GSK1265744 10mg administered in either oral solution fasted, two 5mg tablets fasted, or two 5mg tablets following a moderate meal.

Phase:

Phase 1

Details

Lead Sponsor:

ViiV Healthcare

Collaborators:

GlaxoSmithKline
Shionogi

Treatments:

Cabotegravir